When was Abogen Biosciences founded?

Abogen Biosciences was founded in 2019 and became a unicorn in 2021, reaching the milestone in 2 years. It raised its 1st funding round 1 year after its incorporation.

Where is Abogen Biosciences located?

Abogen Biosciences is headquartered in Suzhou, China.

Who is the current CEO of Abogen Biosciences?

Ying Bo and Dr InBev s of Abogen Biosciences. Ying Bo has also founded 1 company.

Is Abogen Biosciences a funded company?

Abogen Biosciences is a funded company, having raised a total of $1.13B across 5 funding rounds to date. The company's 1st funding round was a $22.4M Series A round, raised on Nov 05, 2020.

When was the latest funding round of Abogen Biosciences?

Abogen Biosciences' latest funding was a Series C round on May 05, 2022, with participation from 1 investor.

Is Abogen Biosciences a Infectious Diseases company?

The primary sectors of Abogen Biosciences are Infectious Diseases, Oncology, Drug Delivery, Immunology and Life Sciences Tech.

Where does Abogen Biosciences rank among its competitors?

Abogen Biosciences ranks 830th amongst 2973 active competitors, of which 1036 are funded. It stands 2nd in terms of total funding among its competitors. The most recent competitor to raise funding was Karyopharm, which secured $30M in Mar, 2026.

Who are the top competitors of Abogen Biosciences?

Abogen Biosciences' top competitors include Jazz Pharmaceuticals, Evotec and Sana Biotechnology. Among them, Karyopharm secured the most recent funding round in March, 2026.

Abogen Biosciences - 2026 Company Profile, Team, Funding & Competitors

Abogen Biosciences is a series C company based in Suzhou (China), founded in 2019 by Ying Bo and Dr InBev. It operates as a Developer of mRNA-based therapeutics for cancer and infectious diseases. Abogen Biosciences has raised $1.13B in funding from investors like SDIC Venture Capital Management, Hillhouse and Temasek. The company has 2973 active competitors, including 1036 funded and 668 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Evotec and Sana Biotechnology.

Sectors and market segments that Abogen Biosciences operate in

Abogen Biosciences serves in the Life Sciences, Sustainability Tech, HealthTech market segments.The primary business model of Abogen Biosciences are:

Company Details

Developer of mRNA-based therapeutics for cancer and infectious diseases. The company has developed proprietary technology platforms in mRNA design, in vitro synthesis, and LNP-based delivery systems to develop targeted therapies for infectious and immuno-oncology indications.

Website: abogenbio.com
Email ID: *****@abogenbio.com

Key Metrics

Founded Year

2019

Location

Suzhou, China

Stage

Series C

Total Funding

$1.13B in 5 rounds

Latest Funding Round

Series C, May 05, 2022, Undisclosed

Investors

SDIC Venture Capital Management & 41 more

Ranked

830^th among 2973 active competitors

Similar Companies

Evotec & 605 more

View Abogen Biosciences' full profile

Abogen Biosciences has raised a total funding of $1.13B over 5 rounds. Its first funding round was on Nov 05, 2020. Its latest funding round was a Series C round on May 05, 2022 for an undisclosed amount. 1 investor participated in its latest round. Abogen Biosciences has 42 institutional investors.

Here is the list of recent funding rounds of Abogen Biosciences:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 05, 2022	Undisclosed	Series C	-	-	-	Chengdu Kanghua Biological Products
Nov 29, 2021	$300M	Series C	-	-	SoftBank Vision Fund, 5Y Capital	Chimera, Mirae Asset, Fortune Ocean, Oriental Fortune Capital, Jinyi Capital, New Frontier, IMO Ventures
Aug 19, 2021	$720M	Series C	-	-	Temasek, GL Ventures, Invesco, Loayal Valley Capital, Yunfeng, Boyu Capital, Lilly Asia Ventures	Youshan Capital, Gaorong Capital, Firstred, Octagon Capital, Kaiser Permanente Ventures, 5Y Capital, MSA Capital, Alwin Capital, Yingke Capital, Tiger Jade Capital, AIHC, Jiangsu Ruihua Investment Holding Group, Legend Holdings, Qiming Venture Partners, HLC, PICC Capital Investment Management, BioTrack Capital, CTS Capital Ventures, Oriental-spring.com

Access funding benchmarks and valuations. Sign up today!

View details of Abogen Biosciences's funding rounds and investors

The founders of Abogen Biosciences are Ying Bo and Dr InBev. Dr InBev and Ying Bo are the CEOs of Abogen Biosciences.

Here are the details of Abogen Biosciences' key team members:

Ying Bo: Co-Founder & Co-CEO of Abogen Biosciences.
Contact Info: 1 email address
Dr InBev: Co-Founder & Co-CEO of Abogen Biosciences.

View details of Abogen Biosciences's Founder profiles and Board Members

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Abogen Biosciences include Jazz Pharmaceuticals, Evotec and Sana Biotechnology. Here is the list of Top 10 competitors of Abogen Biosciences, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, KKR & 14 others	82/100
2nd	Evotec 1993, Hamburg (Germany), Public	AI-driven life science company accelerating drug discovery and development	$25.1M	Mubadala, Gates & 22 others	76/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, Bezos Expeditions & 17 others	75/100
4th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Nextech Invest, Third Rock Ventures & 20 others	72/100
5th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Google Ventures & 15 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Delos Capital Partners ... & 19 others	72/100
8th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	71/100
9th	Karyopharm 2008, Newton (United States), Public	Biopharmaceutical company focused on developing and commercializing innovative cancer therapies	$98.4M	Avidity Partners, Foresite Capital & 16 others	71/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
830th	Abogen Biosciences 2019, Suzhou (China), Series C	Developer of mRNA-based therapeutics for cancer and infectious diseases	$1.13B	Temasek, Invesco & 40 others	42/100